FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 339:551-553 August 20, 1998 Number 8 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Gottlieb, S. S. PubMed Citation

During the 1960s, Sir James W. Black developed propranolol, which the Nobel Committee in 1988 called "the greatest breakthrough when it comes to pharmaceuticals against heart illness since the discovery of digitalis 200 years ago."¹ Black recognized that an agent that blocked the cardiac effects of epinephrine might reduce ischemia and lower the risk of death by decreasing the heart's demand for oxygen. A series of elegant randomized clinical trials reported in the 1980s confirmed the value of Black's insight by showing that beta-blockers improve survival after myocardial infarction.²

In order to focus on the potential therapeutic benefit of beta-blockers, . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Weiner, M, Stump, T E, Callahan, C M, Lewis, J N, McDonald, C J (2005). Pursuing integration of performance measures into electronic medical records: beta-adrenergic receptor antagonist medications. Qual Saf Health Care 14: 99-106 [Abstract] [Full Text]  
• Auerbach, A. D., Goldman, L. (2002). {beta}-Blockers and Reduction of Cardiac Events in Noncardiac Surgery: Scientific Review. JAMA 287: 1435-1444 [Abstract] [Full Text]  
• Auerbach, A. D., Goldman, L. (2002). {beta}-Blockers and Reduction of Cardiac Events in Noncardiac Surgery: Clinical Applications. JAMA 287: 1445-1447 [Abstract] [Full Text]  
• (1998). Do Patients with Contraindications Benefit from Beta-Blockers After MI?. Journal Watch Cardiology 1998: 3-3 [Full Text]  
• (1998). Post MI Beta-Blockers: Time to Rethink ""Contraindications""?. JWatch General 1998: 2-2 [Full Text]